FIMECS Presents at Targeted Protein Degradation Summit 2019
News release Download PDF
Kanagawa, Japan, 8 September 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D., Chief Executive Officer and Chief Scientific Officer of FIMECS, will make a presentation at Targeted Protein Degradation Summit 2019 (22-24 October, 2019 in Boston, MA).
For more information:
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno, CFO and VP of Corporate Development
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan